Thetis Pharmaceuticals LLC
Ridgefield, CT · Founded 2011 · CIK 0001528491 · Biotech · Private
TP-317, a Resolvin E1 (RvE1) lipid therapeutic molecule for pancreatic cancer that clears cellular debris and resolves inflammation
thetispharma.com →- Grants
- $14M
- 17 awards
- Sector median: 1
- Raised
- $14M
- 6 Form D · Jul 2022
- 51 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 15 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,535,000 | |
| Private capital raised | Form D · SEC | $5,665,730 | |
| Private capital raised | Form D · SEC | $1,434,000 | |
| Private capital raised | Form D · SEC | $3,333,851 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $205,992 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $78,301 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients | $205,144 | |
| Private capital raised | Form D · SEC | $795,800 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $1,396,059 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $1,968,042 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of TP-317 for the Treatment of Eosinophilic Esophagitis | $293,722 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients | $1,196,452 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis | $295,609 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $571,983 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis | $1,982,861 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients | $498,366 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Resolvin-Based Therapy for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) | $299,561 | |
| Private capital raised | Form D · SEC | $1,098,320 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 in Ulcerative Colitis | $997,635 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer | $398,404 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 in Ulcerative Colitis | $999,624 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of TP-317 in Ulcerative Colitis | $999,696 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer | $1,725,203 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1446 | Saliogen Therapeutics, Inc. | — | $94M |
| 1447 | BRAINSTORM THERAPEUTICS, INC. | — | — |
| 1448 | Peptilogics | — | $41M |
| 1449 | Thetis Pharmaceuticals LLC | — | $14M |
| 1450 | PANDOMEDX, INC. | — | — |
| 1451 | COMETA THERAPEUTICS INC | — | — |
| 1452 | ProPhase Labs, Inc. | — | $8.4M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michael CarterExecutive Officer
- Cynthia GreenDirector
- Gary MathiasDirector · Executive Officer
- Alan MendelsonDirector
- Walter OgierDirector
- Frank SciavolinoDirector · Executive Officer
- Dennis WillsonDirector
- David WurzerDirector
Patents
- Cyclodextrin Complexes Of Specialized Proresolving Mediatorsapplication
- Cyclodextrin Complexes Of Specialized Proresolving Mediatorsgranted
- Compositions And Methods For Immune-mediated Inflammatory Diseasesapplication
- Compositions And Methods Relating To Salts Of Specialized Pro-resolving Mediatorsgranted
- Compositions And Methods Relating To Salts Of Specialized Pro-resolving Mediatorsgranted
- Compositions And Methods Relating To Salts Of Specialized Pro-resolving Mediatorsgranted
- Compositions And Methods Relating To Salts Of Specialized Pro-resolving Mediatorsgranted
- Compositions And Methods Relating To Salts Of Specialized Pro-resolving Mediatorsgranted
- Mineral Amino-Acid Complexes of Active Agentsgranted
- Amino Acid Salts Of Unsaturated Fatty Acidsapplication
- Compositions and Methods Relating to Ionic Salts of Peptidesapplication
- Compositions and Methods Relating to Ionic Salts of Peptidesgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.